What is RGNX's market cap?

$508.96M, based on the Nov 4 close of $7.71.

Does REGENXBIO pay a dividend?

No regular cash dividend has been paid in the last year.

How much of RGNX is sold short?

10.0M shares, 19.4% of float, as of Oct 15, 2026.

What sector is RGNX in?

Healthcare, in the Biotechnology industry.

NASDAQ · RGNXHealthcareBiotechnology

REGENXBIO Inc. (RGNX)

$7.71+1.05%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$7.75▼ 35.40% in range

Nov 3, 2025Low $5.65 · High $15.98Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

REGENXBIO closed at $7.71 on Nov 4, up 1.05%, 51.8% below its 52-week closing high. Volume of 1.3M shares was 1.01× its 20-day average (close to normal).

Split-adjusted performance: +3.5% over one month, -24.6% over six months, -35.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $108.02M, up 405.7% from a year earlier, with a net margin of 21.0%.

Short interest was 10.0M shares at the Oct 15 settlement, up 4.5% from the prior report (19.4% of float, 6.8 days to cover).

Market cap$509.0M66.0M shares

Revenue · quarter$108.0M+405.7% YoY

Diluted EPS$0.43—

P/E · TTM—P/S 2.9×

Net margin21.0%Gross 99.0%

Dividend yieldNone

52-week range5.65 – 15.98−51.8% from high

Volume1.3M1.01× 20-day avg

Volatility · 60d87.0%Annualised

Short % of float19.4%6.8 days to cover

Net cash$105.5MCash $105.5M

Next earnings—Not scheduled

Split-adjusted performance

1W +6.5%1M +3.5%3M −31.6%6M −24.6%YTD −46.5%1Y −35.7%3Y −46.3%5Y −78.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum47

Revenue growth91

Net margin83

Value (low P/E)—

Size63

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short10.0M+4.5% vs prior

Days to cover6.8Settled Oct 15

% of float19.4%

Short vol. 10d52.0%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
RGNXREGENXBIO	$7.71	+1.05%	−24.6%	+405.7%	21.0%	—	$509.0M
ENTXEntera Bio	$3.11	+1.97%	+148.8%	—	—	—	$540.9M	Compare
EDITEditas Medicine	$2.72	+4.62%	−14.3%	+232.3%	−153.3%	—	$417.7M	Compare
ALLOAllogene Therapeutics	$1.19	+6.25%	−48.5%	—	−919.8%	—	$411.1M	Compare
TECXTectonic Therapeutic	$20.30	+6.95%	−30.0%	—	—	—	$396.9M	Compare
ZURAZura Bio Limited	$4.02	+0.75%	−17.8%	—	—	—	$387.2M	Compare
CCCCC4 Therapeutics	$3.12	−2.80%	+6.5%	+2.8%	−355.9%	—	$383.8M	Compare
FDMT4D Molecular Therapeutics	$12.28	+2.76%	+17.9%	+25106.7%	−1929.0%	—	$678.4M	Compare
AURAAura Biosciences	$6.65	+6.57%	−19.8%	—	—	—	$689.6M	Compare

News about REGENXBIO

All news →

Wall Street Analysts See a 214.55% Upside in Regenxbio (RGNX): Can the Stock Really Move This High?Zacks Investment Research · 17h ago▲ Positive Kuehn Law Encourages Investors of Regenxbio, Inc. to Contact Law FirmGlobeNewswire Inc. · Jul 13, 2026▼ Negative REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNXBenzinga · Apr 15, 2026▼ Negative INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNXGlobeNewswire Inc. · Apr 14, 2026▼ Negative Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. InvestorsGlobeNewswire Inc. · Apr 14, 2026▼ Negative

Quick answers

What does REGENXBIO do?: Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins.
What is RGNX's market cap?: $508.96M, based on the Nov 4 close of $7.71.
Does REGENXBIO pay a dividend?: No regular cash dividend has been paid in the last year.
How much of RGNX is sold short?: 10.0M shares, 19.4% of float, as of Oct 15, 2026.
What sector is RGNX in?: Healthcare, in the Biotechnology industry.

About REGENXBIO

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

HQ: Rockville, MD371 employeesListed Sep 17, 2015regenxbio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology